BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 33934966)

  • 21. Investigating the equivalent performance of biparametric compared to multiparametric MRI in detection of clinically significant prostate cancer.
    Wang B; Gao J; Zhang Q; Zhang C; Liu G; Wei W; Huang H; Fu Y; Li D; Zhang B; Guo H
    Abdom Radiol (NY); 2020 Feb; 45(2):547-555. PubMed ID: 31907568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal cut-off value of perfusion parameters for diagnosing prostate cancer and for assessing aggressiveness associated with Gleason score.
    Cho E; Chung DJ; Yeo DM; Sohn D; Son Y; Kim T; Hahn ST
    Clin Imaging; 2015; 39(5):834-40. PubMed ID: 26001659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation.
    Mowatt G; Scotland G; Boachie C; Cruickshank M; Ford JA; Fraser C; Kurban L; Lam TB; Padhani AR; Royle J; Scheenen TW; Tassie E
    Health Technol Assess; 2013 May; 17(20):vii-xix, 1-281. PubMed ID: 23697373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective evaluation of the value of dynamic contrast enhanced (DCE) imaging for prostate cancer detection, with pathology correlation.
    Al Salmi I; Menezes T; El-Khodary M; Monteiro S; Haider EA; Alabousi A
    Can J Urol; 2020 Jun; 27(3):10220-10227. PubMed ID: 32544044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)-do we still need contrast media?
    Huebner NA; Korn S; Resch I; Grubmüller B; Gross T; Gale R; Kramer G; Poetsch N; Clauser P; Haitel A; Fajkovic H; Shariat SF; Baltzer PA
    Eur Radiol; 2021 Jun; 31(6):3754-3764. PubMed ID: 33263793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiparametric MRI for prostate cancer detection: Preliminary results on quantitative analysis of dynamic contrast enhanced imaging, diffusion-weighted imaging and spectroscopy imaging.
    Fusco R; Sansone M; Petrillo M; Setola SV; Granata V; Botti G; Perdonà S; Borzillo V; Muto P; Petrillo A
    Magn Reson Imaging; 2016 Sep; 34(7):839-45. PubMed ID: 27071309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamic contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging in the activity staging of terminal ileum Crohn's disease.
    Wu YC; Xiao ZB; Lin XH; Zheng XY; Cao DR; Zhang ZS
    World J Gastroenterol; 2020 Oct; 26(39):6057-6073. PubMed ID: 33132655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of multiparametric magnetic resonance imaging to predict postoperative Gleason score upgrading in prostate cancer with Gleason score 3 + 4.
    Kim H; Kim JK; Hong SK; Jeong CW; Ku JH; Kwak C
    World J Urol; 2021 Jun; 39(6):1825-1830. PubMed ID: 32869150
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differentiation of bone metastases from prostate cancer and benign red marrow depositions of the pelvic bone with multiparametric MRI.
    Park S; Park JG; Jun S; Kim H; Kim TS; Kang H
    Magn Reson Imaging; 2020 Nov; 73():118-124. PubMed ID: 32860869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing diagnostic accuracy of luminal water imaging with diffusion-weighted and dynamic contrast-enhanced MRI in prostate cancer: A quantitative MRI study.
    Sabouri S; Chang SD; Goldenberg SL; Savdie R; Jones EC; Black PC; Fazli L; Kozlowski P
    NMR Biomed; 2019 Feb; 32(2):e4048. PubMed ID: 30575145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Multireader Exploratory Evaluation of Individual Pulse Sequence Cancer Detection on Prostate Multiparametric Magnetic Resonance Imaging (MRI).
    Gaur S; Harmon S; Gupta RT; Margolis DJ; Lay N; Mehralivand S; Merino MJ; Wood BJ; Pinto PA; Shih JH; Choyke PL; Turkbey B
    Acad Radiol; 2019 Jan; 26(1):5-14. PubMed ID: 29705281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations?
    Junker D; Steinkohl F; Fritz V; Bektic J; Tokas T; Aigner F; Herrmann TRW; Rieger M; Nagele U
    World J Urol; 2019 Apr; 37(4):691-699. PubMed ID: 30078170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference.
    Vargas HA; Hötker AM; Goldman DA; Moskowitz CS; Gondo T; Matsumoto K; Ehdaie B; Woo S; Fine SW; Reuter VE; Sala E; Hricak H
    Eur Radiol; 2016 Jun; 26(6):1606-12. PubMed ID: 26396111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative diffusion-weighted imaging and dynamic contrast-enhanced characterization of the index lesion with multiparametric MRI in prostate cancer patients.
    Yuan Q; Costa DN; Sénégas J; Xi Y; Wiethoff AJ; Rofsky NM; Roehrborn C; Lenkinski RE; Pedrosa I
    J Magn Reson Imaging; 2017 Mar; 45(3):908-916. PubMed ID: 27442039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic performance of diffusion-weighted imaging combined with dynamic contrast-enhanced magnetic resonance imaging for prostate cancer: a systematic review and meta-analysis.
    Yang L; Tan Y; Dan H; Hu L; Zhang J
    Acta Radiol; 2021 Sep; 62(9):1238-1247. PubMed ID: 32903025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring radiotherapy induced tissue changes in localized prostate cancer by multi-parametric magnetic resonance imaging (MP-MRI).
    Wu X; Reinikainen P; Kapanen M; Vierikko T; Ryymin P; Kellokumpu-Lehtinen PL
    Diagn Interv Imaging; 2019 Nov; 100(11):699-708. PubMed ID: 31257114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.
    Tamada T; Kido A; Yamamoto A; Takeuchi M; Miyaji Y; Moriya T; Sone T
    J Magn Reson Imaging; 2021 Jan; 53(1):283-291. PubMed ID: 32614123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of Prostate Cancer Aggressiveness by Use of the Combination of Quantitative DWI and Dynamic Contrast-Enhanced MRI.
    Hötker AM; Mazaheri Y; Aras Ö; Zheng J; Moskowitz CS; Gondo T; Matsumoto K; Hricak H; Akin O
    AJR Am J Roentgenol; 2016 Apr; 206(4):756-63. PubMed ID: 26900904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3 + 4 prostate cancer.
    Gondo T; Hricak H; Sala E; Zheng J; Moskowitz CS; Bernstein M; Eastham JA; Vargas HA
    Eur Radiol; 2014 Dec; 24(12):3161-70. PubMed ID: 25100337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynamic Contrast-Enhanced MRI-Upgraded Prostate Imaging Reporting and Data System Version 2 Category 3 Peripheral Zone Observations Stratified by a Size Threshold of 15 mm.
    Abreu-Gomez J; Krishna S; Narayanasamy S; Flood TA; McInnes MDF; Schieda N
    AJR Am J Roentgenol; 2019 Oct; 213(4):836-843. PubMed ID: 31120786
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.